TLX Telix Pharmaceuticals Limited
Company Analysis
Latest News
🟢 Telix Pharmaceuticals is trading 10.03% up today after FDA approval of Pixclara for glioma imaging
Telix Pharmaceuticals is trading 10.03% up now at $12.96 after the U.S. FDA approved Pixclara on September 14, 2026, for glioma imaging. - Pixclara is the...
🟢 Telix Pharmaceuticals is trading 8.32% up today after FDA approval of Pixclara for glioma imaging
Telix Pharmaceuticals is trading 8.32% up at $12.76 after the U.S. FDA approved Pixclara on September 14, 2026, for glioma imaging. - Pixclara is the first...
🟢 Telix Pharmaceuticals is trading 4.16% up today after FDA approves Pixclara for glioma imaging
Telix Pharmaceuticals is trading 4.16% up at $11.73 after the FDA approved Pixclara for imaging gliomas. - Pixclara is the first FDA-approved FET-PET imaging...
Telix Wins Its First Brain-Cancer Drug Approval — But Can a Niche Imaging Product Move the Needle for a Billion-Dollar Business?
Shares jumped 7.2% to $12.10 as Telix Pharmaceuticals landed the first-ever FDA-approved imaging drug for brain cancer, handing the Australian...
🟢 Telix Pharmaceuticals is trading 7% up in pre-market after FDA approval of Pixclara for glioma imaging
Telix Pharmaceuticals is trading 7.17% up in pre-market at $12.10 after U.S. FDA approval of Pixclara. - Pixclara is indicated for PET imaging to...
🟢 Telix Pharmaceuticals is trading 6.54% up in after-hours trading as Pixclara’s PDUFA outcome remains unconfirmed
Telix Pharmaceuticals is trading 6.54% up at $12.03 in after-hours trading, supported by broader U.S. indexes gaining more than 0.5%. - It closed at $11.29 on...
🔴 Telix Pharmaceuticals is trading 4.37% down today despite broad U.S. market gains
Telix Pharmaceuticals is trading 4.37% down at $11.38 on September 11, 2026, despite broad U.S. market gains; the precise catalyst remains unclear. - The key...
🟢 Telix Pharmaceuticals is trading 4.17% up today ahead of FDA’s September 11 Pixclara decision
Telix Pharmaceuticals is trading 4.17% up at $12.48 as investors focus on the FDA’s September 11 decision deadline for Pixclara, its brain-cancer imaging...
Telix Rises 5%, Awaiting FDA Decision on Brain Cancer Imaging Agent
Telix Pharmaceuticals shares rose approximately 5% this week. The U.S. Food and Drug Administration (FDA) is expected to announce a decision on the Pixclara...
🟢 Telix Pharmaceuticals is trading 4.72% up in pre-market after completing 350-patient BiPASS enrollment
Telix Pharmaceuticals is trading at $11.99, +4.72% in pre-market after completing enrollment of 350 patients in its Phase 3 BiPASS study. • The company...
Telix Fills Its Prostate Cancer Trial and Gets an FDA Nod — But Can It Turn Imaging Into a Billion-Dollar Franchise?
Shares jumped +6.5% to $11.56 as Telix Pharmaceuticals announced it completed enrollment of 350 patients in its Phase 3 BiPASS study — a late-stage trial...
🟢 Telix Pharmaceuticals is trading 6.5% up today after completing 350-patient Phase 3 BiPASS enrollment
Telix Pharmaceuticals is trading at $11.56, up +6.54% on September 2, 2026, after completing enrollment of 350 patients in the Phase 3 BiPASS study. - Aligned...
🟢 Telix Pharmaceuticals is trading 5% up in pre-market after completing Phase 3 BiPASS enrollment
Telix Pharmaceuticals is trading 5.25% up at $11.42 after announcing completion of patient enrollment in the Phase 3 BiPASS study and alignment with the FDA on...
🟢 Telix Pharmaceuticals is trading 5.47% up in after-hours trading — reason remains unconfirmed
Telix Pharmaceuticals is trading 5.47% up at $11.91 after rising from the August 28 regular-session close of $11.29; the reason remains unconfirmed. -...
🔴 Telix Pharmaceuticals is trading 4.41% down today
Telix Pharmaceuticals is trading 4.41% down at $11.18, based on live price context for August 26, 2026; no clearly dated company announcement was identified as...
🔴 Telix Pharmaceuticals is trading 9.2% down today as potential share issuance raises dilution concerns
Telix Pharmaceuticals is trading 9.2% down at $11.31 after investors reacted negatively to the August 20 announcement of a potential at-the-market equity...
Telix Posts Blowout Earnings, So Why Did Investors Punish the Stock 7% on Dilution Fears
Shares shifted sharply lower on August 21, with Telix Pharmaceuticals (NASDAQ: TLX) falling 7.2% to $11.53 despite reporting half-year results that, on their...
🔴 Telix Pharmaceuticals is trading 7.17% down in pre-market on dilution concerns over new ADS issuance
Telix Pharmaceuticals is trading 7.17% down in pre-market at $11.53 after announcing an at-the-market facility allowing issuance of new ADSs, raising potential...
🟢 Telix Pharmaceuticals is trading 4.6% up in pre-market
Telix Pharmaceuticals is trading at $12.27, up 4.60%, with no clearly reported company-specific catalyst on August 18, 2026. - Half-year results are scheduled...
🔴 Telix Pharmaceuticals is trading 6.7% down in pre-market — no clear catalyst identified
Telix Pharmaceuticals is trading 6.7% down at $11.03 after falling from its August 14, 2026 close of $11.82, with no clear company-specific catalyst identified...